KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice
Medical experts review long-term data from the KEYNOTE-B61 trial on pembrolizumab and lenvatinib, compare its efficacy and safety across non–clear cell RCC subtypes, and discuss dose management and safety relative to the CLEAR trial.
Video content above is prompted by the following:
- Discuss the long-term follow-up data from the phase II 2 KEYNOTE-B61trial investigating pembrolizumab and lenvatinib and its the data’s impact in the first-line setting for advanced nccRCC.
- How does the population size of this trial compare to with others?
Please comment on the recent label change based on this these data.
- Building on the long-term follow-up data from the KEYNOTE-B61 trial, how did the response rates and safety data compare across different nccRCC histologies?
- In your practice, how do you approach dose reductions and treatment duration management?
How does the safety data seen in KEYNOTE B61 compare to with what is was seen in the CLEAR trial?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
